Related Experiment Video
Updated: Oct 16, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Preclinical Study of Immunological Isoxazole Derivatives as a Potential Support for Melanoma Chemotherapy
Izabela Jęśkowiak1, Benita Wiatrak1, Adam Szeląg1
1Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland.
Abstract:
(1) Background: Melanoma is an aggressive neoplasm derived from melanocyte precursors with a high metastatic potential. Responses to chemotherapy and immunotherapy for melanoma remain weak, underlining the urgent need to develop new therapeutic strategies for the treatment of melanoma. (2) Methods: The viability of NHDF and A375 cell cultures after the administration of the tested isoxazole derivatives was assessed after 24-h and 48-h incubation periods with the test compounds in the MTT test. ROS and NO scavenging analyses, a glycoprotein-P activity analysis, a migration assay, a test of apoptosis, and a multiple-criteria decision analysis were also performed. (3) Results: All compounds that were tested resulted in a slower migration of melanoma neoplastic cells. The mechanism of the antitumor activity of the tested compounds was confirmed-i.e., the pro-apoptotic activity of the compounds in A375 cell cultures. Compound O7K qualified for further research. (4) Conclusions: All the tested compounds inhibited the formation of melanoma metastases and demonstrated the ability to reduce the risk of developing drug resistance in the tumor. The MCDA results showed that O7K showed the strongest antitumor activity.
Insights
New isoxazole derivatives show potential in inhibiting melanoma metastasis and reducing drug resistance. Compound O7K demonstrated the strongest antitumor activity, warranting further research for melanoma treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Melanoma is an aggressive skin cancer with high metastatic potential.
- Current treatments like chemotherapy and immunotherapy have limited efficacy.
- Novel therapeutic strategies are urgently needed for melanoma treatment.
Purpose of the Study:
- To evaluate the potential of novel isoxazole derivatives as anti-melanoma agents.
- To investigate the mechanism of action of these compounds.
- To identify lead compounds for further preclinical development.
Main Methods:
- Cell viability assays (MTT test) on NHDF and A375 cells.
- Analysis of reactive oxygen species (ROS) and nitric oxide (NO) scavenging.
- Assessment of P-glycoprotein activity, cell migration, and apoptosis.
- Multiple-criteria decision analysis (MCDA) for compound selection.
Main Results:
- All tested isoxazole derivatives inhibited melanoma cell migration.
- Compounds exhibited pro-apoptotic activity in A375 melanoma cells.
- Compound O7K was identified as the most promising candidate for further study.
Conclusions:
- The tested isoxazole derivatives effectively inhibit melanoma metastasis.
- These compounds may help reduce the risk of developing drug resistance.
- O7K shows significant antitumor activity, indicating its therapeutic potential.
